Selection of potent immunological adjuvants for vaccine construction

Seminars in Cancer Biology

Volumn 6, Issue 6, 1995, Pages 375-385

  McElrath, Margaret Juliana ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvants; Cytokines; Emulsions; Liposomes; Muramyl dipeptides; QS21

Indexed keywords

IMMUNOLOGICAL ADJUVANT; RECOMBINANT VACCINE;

ACTIVE IMMUNIZATION; CHEMISTRY; COMPARATIVE STUDY; HUMAN; IMMUNOLOGY; NEOPLASM; REVIEW;

ADJUVANTS, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY, ACTIVE; NEOPLASMS; VACCINES, SYNTHETIC;

EID: 0029422476     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/1044-579X(95)90007-1     Document Type: Article

References (74)

1. Berd, D, Maguire HC, Mastrangelo MJ (1986) Induction of cell- mediated immunity to autologous melanoma cells and regression of metastasis after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46:2572-2579
2. Livingston PO, Albino AP, Cheng TJC (1985) Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer 55:713-719
3. Le Moignic, Pinoy (1916) Application to man of vaccines consisting of emulsions in fatty substances (lipo-vaccines). Comp Rend Soc Biol 79:352
4. Chang SP, Nikaido CM, Hashimoto AC, Hashiro CQ, Yokota BT, Hui GSN (1994) Regulation of antibody specificity to Plasodium falciparum merozoite surface protein-1 by adjuvant and MHC haplotype. J Immunol 152:3483-3490
5. Goldenthal KL, Cavagnaro JA, Alving CR, Vogel FR (1993) Safety evaluation of vaccine adjuvants: National Cooperative Vaccine Development Meeting Working Group. AIDS Res Hum Retroviruses 9: S47-S51
6. Glenny AT, Pope CG, Waddington H, Wallace U (1926) XXII - the antigenic value of toxoid precipitated by potassium alum. J Pathol Bacterial 29:38-39
7. Edsall G (1966) Application of immunological principles to immunization practices. Med Clin North Am 49:1729-1743
8. Vogel FR, Powell MF (1994) A compendium of vaccine adjuvants and excipients, in Vaccine Design (Powell MF, Newman MJ, eds) pp 1-92. Plenum Publishing Corporation, New York, NY
9. Hem SL, White JL (1994) Characterization of aluminum hydroxide for use as an adjuvant in parenteral vaccines. J Parent Sci Technol 38:2
10. Davenport FM, Hennessy AV, Askin FB (1968) Lack of adjuvant effect of Alum on purified influenza virus hemagglutinins in man. J Immunol 100:1139-1140
11. Nicholson KG, Tyrrell DAJ, Harrison P, Potter CW, Jennings R, Clark A, Shild GC, Wood JM, Yetts R, Seagroatt V, Huggins A, Anderson SG, et al (1979) Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: Serological responses and clinical reactions. J Biol Stand 7:123-136
12. Freund J, Casals J, Hosmer EP (1937) Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil. Proc Soc Exp Biol Med 37:509
13. Ellouz FA, Adam A, Ciorbaru R, Lederer E (1974) Minimal structural requirements for adjuvant activity of bacterial pepti- doglycan derivatives. Biochem Biophys Res Commun 59:1317-1325
14. Waters RV, Terrell TG, Jones GH (1986) Uvetitis induction in the rabbit in muramyl dipeptide. Infect Immun 44:344
15. Byars NE (1986) Two adjuvant active muramyl dipeptide analogues induce differential production of lymphocyte activating factor and a factor causing distress in guinea pigs. Infect Immun 44:344
16. Allison AC, Byars NE (1990) Adjuvants for a new generation of vaccines, in New Generation Vaccines (Woodrow GC, Levine MM, eds) pp 129-140. Marcel Dekker, Inc.
17. Johnson AG (1994) Molecular adjuvants and immunomodula- tors: New approaches to immunization. Clin Micro Rev 7:277-289
18. Allison AC, Byars NE (1986) An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J Immunol Meth 95:157-168
19. Ledgate DM, Fu RC, Byars NE, Foster LC, Fleitman JS (1989) Formulation of vaccine adjuvant muramyldipeptides. 3. Processing optimization, characterization and bioactivity of an emulsion vehicle. Pharm Research 6:748-752
20. Hunter RL, Bennett B (1984) The adjuvant activity of nonionic block polymer surfactants. J Immunol 133:3167-3175
21. Byars NE, Allison AC (1987) Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity. Vaccine 223-228
22. Marx PA, Pedersen NC, Lerche NW, Osbom KG, Lowensteine LJ, Lackner AA, Maul DH, Kwang HS, Kluge JD, Zaiss CP, et al (1986) Prevention of simian acquired immune deficiency syndrome with a formalin-inactivated type D retrovirus vaccine. J Virol, in press
23. Desrosiers RC, Wyand MS, Kodama T, Ringler DJ, Arthur LO, Sehgal PK, Letvin N, King NW, Daniel MD (1989) Vaccine protection against simian immunodeficiency virus infection. Proc Nad Acad Sci USA 86:6353-6357
24. Girard M, Kieny M-P, Pinter A, Barre-Sinoussi F, Nara P, Kolbe H, Kusumi K, Chupat A, Reinhart T, Muchmore E, et al (1991) Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci USA 345:542-546
25. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK (1993) Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 11:293-306
26. Beebe GW, Simon AH, Vivona LS (1972) Long-term mortality follow-up of army recruits who received adjuvant influenza virus vaccine in 1951-1953. Am J Epidemiol 95:337
27. Greenberg L, Fleming DS (1947) Increased efficiency of diphtheria toxoid when combined with pertussis vaccine. Can J Public Health 38:279-286
28. Landy MA, Johnson AG, Webster ME, Sagin JF (1955) Studies on die O antigen of Salmonella typhosa. II. Immunological properties of the purified antigen. J Immunol 74:466-478
29. Webster ME, Sagin JF, Landy M, Johnson AG (1955) Studies on the O andgen of Salmonella typhosa. I. Isoladon and purification of the antigen. J Immunol 74:455-465
30. Galanos C, Leuderitz O, Rietschel ET, Westphal O, Brade H, Brade L, Freudenberg MA, Schade UF, Imoto M, Yoshimura H, Kusumoto S, Shiba T (1985) Synthetic and natural Escherichia coti free lipid A express identical endotoxic activities. Eur J Biochem 148:1-5
31. Ulrich JT, Masihi KN, Lange W (1988) Mechanisms of nonspecific resistance to microbial infections induced by trehalose dimycolate (TDM) and monophosphoryl lipid A (MPL). Adv Biosci 68:167-178
32. Allison AC, Gregoriadis G (1974) Liposomes as immunological adjuvants. Nature 252:252
33. Gregoriadis S (1990) Immunological adjuvants: A role for liposomes. Immunol Today 11:89-98
34. El Guink N, Kris RM, Goodman-Snitkoff G, Small PA, Mannino RJ (1987) Intranasal Immunization with proteoliposomes protects against influenza. Vaccine 7:147-151
35. Thibodeau L, Tremblay C, Lachapelle L (1991) Une immunisation orale et parenterale avec l’iminunosome-VIH induit une secretion d’IgA specifique du VIH-1 dans la salive et la production d’IgA circulants chez le sons et le lapin. C R Acad Sci Paris 313:389-394
36. Noguchi Y, Noguchi T, Sato T, et al (1991) Priming for in vitro and in vivo anti-human T lymphotropic virus type I cellular immunity by virus-related protein reconstituted into liposome. J Immunol 146:3599-3503
37. Richou R.Jensen R, Belin C (1964) Recherches sur la saponine, substance adjuvante et stimulante de l’immunite. Rev d’lmmu- nol Paris 28:49-62
38. Morein B, Sandquist B, Hoglund S, Kalsgaard K, Osterhaus A (1984) Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308:457-460
39. Bomford R (1992) Adjuvants for viral vaccines. Med Virol 2:169-174
40. Kensil CR, Patel U, Lennick M, Marciani D (1991) Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol 146:431-437
41. Powell MF, Cleland JL, Eastman DJ, Lim A, Newman MJ, Nunberg JH, Weissburg RP, Vennari JC, Wrin T, Berman PW (1994) Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-l QS21 vaccine in baboons. AIDS Res Hum Retroviruses 10: S105-S108
42. Wu J-Y, Gardiner BH, Murphy CI, Seals JR, Kensil CR, Recchia J, Beltz GA, Newman GW, Newman MJ (1992) Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J Immunol 148:1519
43. Bomford R, Stapleton M, Winsor S, McKnight A, Andronova T (1992) The control of the antibody isotype response to recombinant human immunodeficiency virus gpl20 antigen by adjuvants. AIDS Res Human Retroviruses 8:1765-1771
44. Heath AW, Playfair JHL (1992) Cytokines as immunological adjuvants. Vaccine 10:427-434
45. Weinberg A, Merigan TC (1988) Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. J Immunol 120:294-299
46. Heath AW, Devey, Brown IN, Richards CE, Playfair JHL (1989) Interferon-gamma as an adjuvant in immunocompromised mice. Immunology 67:520-524
47. Afonso LCC, Scharton TM, Vieira ZQ, Wysocka M, Trinchieri G, Scott P (1994) The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263:235
48. Wynn TA, Cheever AW, Jankovic D, Poindexter RW, Caspar P, Lewis FA, Sher A (1995) An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature 376:594-596
49. Wintsch J, Chaignot G-L, Braun DG, el al (1991) Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine. J Infect Dis 163:219-225
50. Kahn JO, Sinangil F, Baenziger J, Murcar N, Wynne D, Coleman RL, Steimer KS, Dekker CL, Chernoff D (1994) Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gpl20 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J Infect Dis 170:1288-1291
51. Keefer M, McElrath J, Graham B, Matthews T, Chernoff D, Dolin R, NIAID AIDS Vaccine Clinical Trials Network (1993) Safety and immunogenicity of a preventive HIV-1 vaccine candidate, ENV 2-3, in combination with MTP-PE/MF59. Poster, 1st National Conference on Human Retroviruses and Related Infections, Washington, DC, December, [103]
52. Graham B, Keefer M, McElrath J, Matthews T, Schwartz D, Gorse G, Sposto R, Chernoff D, NIAID AIDS Vaccine Clinical Trials Network (1993) Phase I trial of native HIV-1 SF-2 rgpl20 candidate vaccine. Poster, 9th International Conference on AIDS/4th STD World Congress, Berlin, Germany, June 250[PO-A29-0692]
53. McElrath J, Keefer M, Greenberg P, Sposto R, Chernoff D, Steimer K, NIAID AIDS Evaluation Group (1993) Evaluation of a nonglycosolated yeast-derived envelope vaccine on HIV-1 specific immunity in a randomized, blinded, controlled HIV-1 seropositive trial. Poster, 9th International Conference on AIDS/4di STD World Congress, Berlin, Germany, June [PO- A28-0670]
54. Van Nest G, Walker C, Steimer K, Baenziger J, Burke RL, Ott G (1994) Microfluidized oil emulsions as adjuvants for HIV and other human vaccines. AIDS Res Hum Retroviruses 10: S115
55. McElrath MJ, Corey L, Clements ML, Belshe R, Keefer M, Graham B, Fast P, Duliege AM, Francis D, NIAID AIDS Vaccine Clinical Trials Network (1994) A Phase II HIV vaccine trial in seronegative volunteers: Expanded safety and immunogenicity evaluation of two rgpl20 vaccines. Presentation, Keystone Symposia on Molecular and Cellular Biology: Prevention and Treatment of AIDS, January Q412]
56. Langenberg AGM, Burke RL, Adair SF, Sekulovich R, Tigges M, Dekker CL, Corey L (1995) A recombinant glycoprotein vaccine for herpes simplex type 2: Safety and efficacy. Ann Intern Med 122:889-898
57. Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau H, Lind S (1988) Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 48:5883-5893
58. Mitchell MS, Harel W, Kempf RA, Hu E, Kan-Mitchell J, Boswell WD, Dean G, Stevenson L (1990) Active-specific immunotherapy for melanoma. J Clin Oncol 8:856-869
59. Rickman LS, Gordon DM, Wistar R Jr, Krzych U, Gross M, Hollingdale MR, Egan JE, Chulay JD, Hoffman SL (1991) Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet 337:998-1001
60. Fries LF, Gordon DM, Richards RL, Egan JE, Hollingdale MR, Gross M, Silverman C, Alving CR (1992) Liposomal malaria vaccine in humans: A safe and potent adjuvant strategy. Proc Nad Acad Sci USA 89:358-362
61. Powell MF, Eastman DJ, Lim A, Lucas C, Peterson M, Vennari J, Weissburg RP, Wrin T, Kensil CR, Newman MJ, Nunberg J, Cleland JL, Gregory TJ, Berman PW (1995) Effect of adjuvants on immunogenicity of MN recombinant glycoprotein 120 in guinea pigs. AIDS Res Hum Retroviruses 11:203-209
62. Adluri S, Helling F, Ogata S, Zhang S, Itzkowitz SH, Lloyd KO, Livingston PO (1995) Immunogenicity of synthetic “IT-KLH and sTn-KLN conjugates in colorectal carcinoma patients. Cancer Immunol Immunother 41:185-192
63. Meuer SC, Dumann H, Meyer zum Buschcnfelde KH, Kohler H (1989) Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet 1:15-18
64. Jungers P, Devilier P, Salomon H, Cerisier JE, Courouce AM (1994) Randomised placebo-controlled Lrial of recombinant interleukin-2 in chronic uraemic patients who are non- responders to hepatitis B vaccine. Lancet 344:856-857
65. Blankenstijn PJ, Van HattumJ, Boland GJ, et al (1993) Hepatitis B vaccination of non-responder dialysis patients with recombinant hepatitis B vaccine in combination with interleukin-2. J Am Soc Nephrol 4:334A
66. Rose RM, Rey-Martinez J, Croteau C, Silvestri RC, Haley K, DePamphilis J, Siber GR, et al (1992) Failure of recombinant Interleukin-2 to augment the primary humoral response to a recombinant hepatitis B vaccine in healthy adults. J Infect Dis 165:775-777
67. Provinciali M, Di Stefano G, Colombo M, Delia Bitta R, Fabris N (1994) Adjuvant effect of low-dose interleukin-2 on antibody response to influenza virus vaccination in healthy elderly subjects. Mech Ageing Dev 77:75-82
68. Quiroga JA, Castillo I, Porres JC, Casado S, S’aez F, Garcia- Mart’inez M, M G’omez, Inglada L, S’anchez-Sicilia L, Mora A, et al (1990) Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. Hepatology 12:661-663
69. Murphey-Corb M, Ohkawa S, Wilson L, Bohm R, Detrick B (1993) Comparative immune responses in macaques immunized with inactivated SIV in combination with 9 different adjuvants. AIDS Res Hum Retroviruses 9: S92
70. Murphey-Corb M, Ohkawa S, Martin L, Wilson L, Bohm R, Blanchard J, Detrick B, Vogel F, Schultlz LA, et al (1994) Comparative efficacy of a whole killed SIV vaccine in combination with various adjuvants. AIDS Res Hum Retroviruses 10: S115
71. Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, Longenecker BM, Yao TJ, Oettgen HF, Livingston PO (1995) GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvants QS-21. Cancer Res 55:2783-2788
72. Livingston PO, Adluri S, Zhang S, Chapman P, Raychaudhuri S, Merritt JA (1995) Impact of immunological adjuvants and administration route on HAMA response after immunization with murine monoclonal antibody melimmune-1 in melanoma patients. Vaccine Research 4:1-8
73. Livingston PO, Koganty R, Longenecker BM, Lloyd KO, Calves M (1992) Studies on die immunogenicity of synthetic and natural Thomsen-Friedenreich (TF) antigens in mice: Augmentation of the response by quil A and SAF-m adjuvants and analysis of the specificity of the responses. Vaccine Res 1:99-109
74. Livingston PO, Adluri S, Raychaudhuri S, Hughes MH, Calves MJ, Merritt JA (1994) A Phase I trial of the immunological adjuvant SAF-m in melanoma patients vaccinated with the antiidiotype antibody MELIMMUNE-1. Vaccine Res 3:71-81